MYC and lymphoma: Given that our work found that inhibition of FAO is a therapeutic strategy against MYC-overexpressing TNBC (Camarda et al., 2016), and a separate study found similar results in a model of MYC-driven lymphoma (Pacilli et al., 2013), it will be interesting to determine if this strategy could be expanded to MYC-driven HB and/or HCC.